<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04075500</url>
  </required_header>
  <id_info>
    <org_study_id>AKKNeuro2019July</org_study_id>
    <nct_id>NCT04075500</nct_id>
  </id_info>
  <brief_title>Optimal Detection of Atrial Fibrillation in TIA</brief_title>
  <acronym>ODEA-TIA</acronym>
  <official_title>Optimal Detection of Atrial Fibrillation in Transient Ischemic Attack</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alfried Krupp Krankenhaus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alfried Krupp Krankenhaus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transient ischemic attack (TIA) is a common neurologic emergency. Although the detection of&#xD;
      atrial fibrillation (AF) has identical consequences for preventive therapy in patients with&#xD;
      ischemic stroke and TIA, the management setting and diagnostic pathways frequently differ&#xD;
      substantially between both manifestations. Despite these differences between stroke and TIA&#xD;
      patients, previous studies have investigated diagnostic work-up for AF primarily in stroke&#xD;
      patients. Thus, there is no common practice or &quot;gold standard&quot; of rhythm monitoring for TIA&#xD;
      patients in most healthcare systems and the optimal method and duration of cardiac monitoring&#xD;
      for TIA patients is currently unknown. This is likely to result in a substantial&#xD;
      under-diagnosis of AF in TIA patients, failure to initiate appropriate secondary preventive&#xD;
      medication (i.e. anticoagulation) and ultimately the occurrence of many otherwise preventable&#xD;
      strokes.&#xD;
&#xD;
      The primary research question of the trial is whether prolonged ECG recording (intervention)&#xD;
      significantly increases the rate of detection of paroxysmal AF compared to 24 h&#xD;
      electrocardiogram (ECG) monitoring (control) 6 months after start of monitoring in patients&#xD;
      with recent TIA. The co-primary question of the trial is whether 28 d non-invasive continuous&#xD;
      ECG monitoring is non-inferior to ECG recording using an implanted event recorder for AF&#xD;
      detection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transient ischemic attacks (TIA) are a common neurologic emergency. Clinical management&#xD;
      guidelines recommend oral anticoagulation for TIA patients suffering from atrial fibrillation&#xD;
      (AF). Therefore, a diagnosis of AF in TIA patients has a major impact on the choice of&#xD;
      adequate secondary stroke prevention. However, detection of paroxysmal AF in patients with&#xD;
      TIA can be challenging. AF remains undetected in a relevant proportion of stroke and TIA&#xD;
      patients using current routine diagnostic procedures. The actual prevalence of AF in TIA&#xD;
      patients is unknown.&#xD;
&#xD;
      Although the detection of AF has identical consequences for preventive therapy in patients&#xD;
      with ischemic stroke and TIA, the management setting and diagnostic pathways frequently&#xD;
      differ substantially between both manifestations. So far, only limited data exist on AF&#xD;
      detection after TIA specifically, and the best method for diagnosis of AF has not been&#xD;
      established. The usefulness of prolonged rhythm monitoring using event recorders or&#xD;
      non-invasive continuous ECG in TIA patients has not been determined. While the use of an AF&#xD;
      detection tool in TIA patients is desirable, an adequate use of resources of AF detection&#xD;
      technologies in unselected TIA patients may be needed for this large scale health care&#xD;
      problem. Identifying TIA patients that are at increased risk of suffering from AF using&#xD;
      clinical and blood-based biomarkers and therefore most likely to benefit from such diagnostic&#xD;
      procedures would be useful.&#xD;
&#xD;
      The primary research question of the trial is whether prolonged ECG recording (intervention)&#xD;
      significantly increases the rate of detection of pAF compared to 24 h ECG monitoring&#xD;
      (control) 6 months after start of monitoring in patients with recent TIA. The co-primary&#xD;
      question of the trial is whether 28 d non-invasive continuous ECG monitoring is non-inferior&#xD;
      to ECG recording using an implanted event recorder for AF detection.&#xD;
&#xD;
      The ODEA-TIA trial is an investigator initiated prospective, multicentre, randomized, open&#xD;
      study with blinded outcome assessment comparing different diagnostic methods for detection of&#xD;
      paroxysmal AF in patients with recent TIA. The primary endpoint is the rate of AF detection&#xD;
      during the 6 months after randomization. Approximately 40 centers in Europe (e.g. UK,&#xD;
      Germany, and Spain) will participate in this trial. Patients with a recent TIA fulfilling the&#xD;
      eligibility criteria (see below) will be randomized in a 1:1:1 fashion between 24 h&#xD;
      arrhythmia monitoring (control arm) and the two procedures for prolonged ECG monitoring&#xD;
      (interventional arms). That means we have two interventional arms, patients receiving either&#xD;
      continuous 28d non-invasive ECG monitoring or ECG event recording using a subcutaneously&#xD;
      implanted event recorder.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Patient will be randomized to either receive 24-h Holter Monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). Patient will either undergo 28-day ECG recording using a commercially available Holter Recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of newly detected AF at 6 month after study enrolment in patients with recent TIA</measure>
    <time_frame>6 month</time_frame>
    <description>Self reported or by other means detected newly AF</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of AF in TIA patients as determined by prolongend ECG Monitoring techniques</measure>
    <time_frame>24 month</time_frame>
    <description>Self reported or by other means detected newly AF</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of newly detected AF at 12 and 24 month after study enrolment in patients with recent TIA</measure>
    <time_frame>12 and 24 month</time_frame>
    <description>Self reported or by other means detected newly AF in longterm ECG Monitoring</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1434</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control arm, 24-h Holter monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Interventional arms, prolonged cardiac monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>24-h Holter monitoring</intervention_name>
    <description>Patients will be randomized to either receive 24-h Holter monitoring or receive one of the two modes for prolonged ECG recording (interventional arms). There are two interventional arms. Patients will either undergo 28-day ECG recording using a commercially available Holter recorder that can function as a non-invasive ECG patch or receive an implantable cardiac device (REVEAL LINQ).</description>
    <arm_group_label>Arm 2</arm_group_label>
    <other_name>Prolonged cardiac monitoring 28-day ECG</other_name>
    <other_name>Prolonged cardiac monitoring implantable cardiac device</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:&#xD;
&#xD;
        Study Population Patients with a recent TIA will be enrolled during a period of&#xD;
        approximately 24 months at participating European stroke centres. TIA patients may be&#xD;
        enrolled after initial management as inpatients or outpatients. Consecutive screening and&#xD;
        enrolment will be strongly encouraged and a screening log will be implemented at each site.&#xD;
&#xD;
        Inclusion Criteria&#xD;
&#xD;
          -  Written informed consent by patient.&#xD;
&#xD;
          -  Age ≥ 50 years.&#xD;
&#xD;
          -  TIA diagnosed by a stroke physician defined as rapidly developing clinical signs of&#xD;
             focal or global disturbances of cerebral function, lasting less than 24 hours with no&#xD;
             apparent non-vascular cause and without evidence of recent brain infarction on&#xD;
             available neuroimaging.&#xD;
&#xD;
          -  12-channel ECG available before enrolment&#xD;
&#xD;
          -  Brain imaging without acute infarct available before enrolment (CCT or cranial MRI)&#xD;
&#xD;
          -  Vascular imaging of cervical vessels performed&#xD;
&#xD;
          -  Enrolment within 28 days after index episode. Exclusion Criteria&#xD;
&#xD;
          -  Previously documented history of AF&#xD;
&#xD;
          -  Ischemic stroke within the last 6 months before enrolment&#xD;
&#xD;
          -  Evidence of recent infarction on neuroimaging corresponding to symptoms at time of&#xD;
             enrolment (e.g. DWI positive lesion on MRI scan)&#xD;
&#xD;
          -  Pre-screening monitoring for cardiac arrhythmias lasting ≥72 hours&#xD;
&#xD;
          -  AF lasting &gt; 30 s on a 12 channel ECG or other ECG recording technique prior to&#xD;
             enrolment&#xD;
&#xD;
          -  Life expectancy less than 1 year.&#xD;
&#xD;
          -  Significant stenosis &gt; 50% in intracranial or extracranial vessels which, in the&#xD;
             opinion of the investigator, is the likely cause of the patients TIA.&#xD;
&#xD;
          -  Severely disabled patients (i.e. modified Rankin Score &gt;3)&#xD;
&#xD;
          -  Lack of therapeutic consequence in case of diagnosis of AF (e.g. other indication for&#xD;
             long term anticoagulation&#xD;
&#xD;
          -  Pacemaker or Implanted Cardiac Defibrillator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roland Veltkamp, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Initiator of study, leader PI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Roland Veltkamp, MD</last_name>
    <phone>+49-201-434-41410</phone>
    <email>Roland.veltkamp@krupp-krankenhaus.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Birgit Lyss</last_name>
    <phone>+49-201-434-41418</phone>
    <email>Birgit.Lyss@krupp-krankenhaus.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, Neurologie</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Johannes Schiefer, MD</last_name>
      <phone>+49-241-8089630</phone>
    </contact>
    <investigator>
      <last_name>Johannes Schiefer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhön Klinikum Campus Bad Neustadt</name>
      <address>
        <city>Bad Neustadt An Der Saale</city>
        <zip>97616</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hassan Soda, MD</last_name>
      <phone>+49-9771-90800-9771</phone>
    </contact>
    <investigator>
      <last_name>Hassan Soda, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vivantes Klinikum Neukölln</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Darius Nabawi, MD</last_name>
      <phone>+49-30-130-142023</phone>
    </contact>
    <investigator>
      <last_name>Darius Nabawi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum Dortmund, Klinikzentrum Mitte / Neurologie</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gernot Reimann, MD</last_name>
      <phone>+49-231-953-0</phone>
    </contact>
    <investigator>
      <last_name>Gernot Reimann, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland Veltkamp, MD</last_name>
      <phone>+49-201-434-41410</phone>
      <email>Roland.Veltkamp@krupp-krankenhaus.de</email>
    </contact>
    <investigator>
      <last_name>Roland Veltkamp, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Heidelberg, Neurologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jan Purrucker, MD</last_name>
      <phone>+46-6221-567504</phone>
    </contact>
    <investigator>
      <last_name>Jan Purrucker, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein, Campus Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Georg Royl, MD</last_name>
      <phone>+49-451-5000</phone>
    </contact>
    <investigator>
      <last_name>Georg Royl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 28, 2019</study_first_submitted>
  <study_first_submitted_qc>August 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 30, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>atrial fibrillation</keyword>
  <keyword>monitoring</keyword>
  <keyword>ECG</keyword>
  <keyword>ischemic attack</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

